Cite

    Walker, A. et al. (n.d.). A benefit–risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy. Current medical research and opinion. pp. 629-635. [Online].